A novel lidocaine patch (NAL1282) was developed for the treatment of postherpetic neuralgia. NAL1282 prototypes selected through in vitro skin permeation study using hairless mouse and Yucatan micropig skins demonstrated the improved adhesion strength and self adhesion properties compared to Lidoderm®. The pharmacokinetic profiles, safety, and tolerability of the prototypes of NAL1282 Lidocaine Patch in healthy human subjects were assessed in comparison with commercially available lidocaine patch, Lidoderm®. In human pharmacokinetic studies, one of NAL 1282 prototypes (NAL1282-2) demonstrated lidocaine plasma concentration profile similar to that of Lidoderm® without significant adverse effects including skin irritation.In conclusion, these data suggest that NAL 1282 is a new and significantly improved lidocaine patch having superior adhesion profiles, skin permeation, and safety profiles compared to those of Lidoderm®.
展开▼
